Tebipenem (hydrate)
(Synonyms: LJC 11,036, SPR859, TBPM) 目录号 : GC49105A carbenapenem antibiotic
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tebipenem is a carbenapenem antibiotic.1,2 It is active against a panel of clinical isolates from a variety of bacterial species (MIC50s = ≤0.0039-8 µg/ml), including methicillin-resistant strains of S. aureus and S. epidermidis and penicillin-resistant S. pneumoniae.1 Tebipenem inhibits β-lactamase in a concentration-dependent manner.2 It decreases the number of colony forming units (CFUs) in the lungs in a mouse model of penicillin-resistant S. pneumoniae infection when administered at doses ranging from 0.32 to 3.2 mg/kg.1
1.Fujimoto, K., Takemoto, K., Hatano, K., et al.Novel carbapenem antibiotics for parenteral and oral applications: In vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animalsAntimicrob. Agents Chemother.57(2)697-707(2013) 2.Hazra, S., Xu, H., and Blanchard, J.S.Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosisBiochemistry53(22)3671-3678(2014)
Cas No. | N/A | SDF | |
别名 | LJC 11,036, SPR859, TBPM | ||
Canonical SMILES | OC(C1=C(SC2CN(C3=NCCS3)C2)[C@H](C)[C@@]([C@]4([C@H](O)C)[H])([H])N1C4=O)=O.OOC(C1=C(SC2CN(C3=NCCS3)C2)[C@H](C)[C@@]([C@]4([C@H](O)C)[H])([H])N1C4=O)=O.O | ||
分子式 | C16H21N3O4S2·XH2O | 分子量 | 383.5 |
溶解度 | DMSO: 1 mg/ml,PBS (pH 7.2): 1 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6076 mL | 13.0378 mL | 26.0756 mL |
5 mM | 0.5215 mL | 2.6076 mL | 5.2151 mL |
10 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Effect of new oral antimicrobial agents in outpatient treatment of pneumonia in children]
Jpn J Antibiot 2014 Jun;67(3):157-66.PMID:25163249doi
In November 2004, "Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan" was published ahead of the rest of the world, by Japanese Society of Pediatric Pulmonology/Japanese Society for Pediatric Infectious Diseases, based on the data on causative organisms in the lower respiratory tract. In its 2011 version, classification of the severity of pneumonia was renewed based on the latest information. As a result, many types of pneumonia in children are now classified as mild or moderate. This means that many patients who might have conventionally required hospital treatment can now be managed on an outpatient basis. The reason for realization of the wider range of outpatient treatment is the availability of two new oral antimicrobial agents, Tebipenem pivoxil and tosufloxacin tosilate hydrate, for the treatment of infections in children. Analysis of data on medical expenses shows a decreased rate of hospitalization due to pneumonia year by year after launch of these two drugs, suggesting that these drugs have contributed to wider range of outpatient treatment. This manuscript discusses the effect of Tebipenem pivoxil and tosufloxacin tosilate hydrate in the treatment of pneumonia.